Patent Attorney's Docket No. 030708-035

TATES PATENT AND TRADEMARK OFFICE

	RECEIVED
	OCT 3 0 2001
Group Art Unit: 1646	TECH CENTER 1600/2900
Examiner: O. Chernyshev	12/c

REPLY AND AMENDMENT

Assistant Commissioner for Patents Washington, D.C. 20231

NEUROTRYPSIN

In re Patent Application of

Application No.: 09/403,724

Peter SONDEREGGER

Filed: October 26, 1999

Sir:

For:

In complete response to the Official Action issued July 26, 2001, please amend the above-identified application as follows:

IN THE ABSTRACT:

Please insert the Abstract of the Disclosure attached to the end of the Reply and Amendment at the end of the application papers.

IN THE SPECIFICATION:

Page 1, amend the fifth full paragraph (beginning at line 17, shown as line 26 on the page) as follows:

The newly found neurotrypsins

- neurotrypsin of the human (compound of the formula I, SEQ ID NO: 1),
- neurotrypsin of the mouse (compound of the formula II, SEQ ID NO: 3) differ structurally very much from the so far known serine proteases.